Amarin Returns to Profitability in Q3 Following Corporate Restructuring
Amarin (AMRN) reported its first profitable quarter in two years during Q3 2026, driven by significant cost-cutting measures and successful international partnerships. The company reduced operating expenses by approximately 44% year-over-year through corporate restructuring, resulting in $9 million in operating cash flow and a net income of $245,000 despite competitive pricing pressures in the U.S. Growth was bolstered by Amarin's partnership with Recordati, which helped drive a 68% year-over-year increase in European demand for its cardiovascular drug, VAZKEPA. While a Phase III clinical trial for oncology applications missed its primary endpoint regarding progression-free survival, it demonstrated a statistically significant 32% lower hazard of death in overall survival for patients with colorectal cancer liver metastases. With zero debt and four consecutive quarters of positive cash flow, Amarin is now evaluating capital deployment options, including potential share repurchases. The company maintains patent protection through 2039, providing a long-term runway for its international commercial model.
Topics: cost restructuring earnings report international expansion pharmaceuticals profitability